HER-2/neu assessment in primary chemotherapy treated breast carcinoma: No evidence of gene profile changing

Breast Cancer Research and Treatment

Volumn 80, Issue 2, 2003, Pages 207-214

  Dagrada, Gian Paolo ^a   Mezzelani, Alessandra ^a   Alasio, Loredana ^a   Ruggeri, Mario ^a   Romanò, Roberta ^a   Pierotti, Marco A ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Archival smears; Fluorescent in situ hybridization (FISH); HER 2 neu; Homogeneously staining regions (HSR); Immunocytochemistry (ICC); Tissue sections

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; NEU DIFFERENTIATION FACTOR; ONCOPROTEIN; PACLITAXEL;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CHROMOSOME 17Q; CLINICAL TRIAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PACLITAXEL;

EID: 0037998712     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024579206250     Document Type: Article

References (32)

1. Harari D, Yarden Y: Molecular mechanisms underlying Erb-2/HER-2 action in breast cancer. Oncogene 19: 6102-6114, 2000
2. Harris RA, Eichholtz TJ, Hiles ID, Page MJ, O'Hare MJ: New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer 80: 477-484, 1999
3. Hutchinson JN, Muller WJ: Transgenic mouse models of human breast cancer. Oncogene 19: 6130-6137, 2000
4. Slamon DJ, Clark MG, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu. Oncogene Sci 235: 177-182, 1987
5. Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol 3: 187-144, 2002
6. Bankfalvi A, Simon R, Brandt B, Burger H, Vollmer I, Dockhorn-Dworniczak B, Lelle RJ, Boecker W: Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 37: 411-419, 2000
7. Bose S, Mohammed M, Shintaku P, Ran PN: HER-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/HER-2/neu polysomy. Breast J 7: 337-344, 2001
8. Farabegoli F, Ceccarelli C, Santini D, Baldini N, Taffurelli M, Marrano D, Treré D, Derenzini M: c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. Int J Cancer 84: 273-277, 1999
9. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17: 1974-1982, 1999
10. Jimenez RE, Wallis T, Tabasczka P, Visscher DW: Determination of HER-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13: 37-45, 2000
11. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML: HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 5: 191-192, 2000
12. Kobayashi M, Ooi A, Oda Y, Nakanishi I: Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed. paraffin-embedded tissues. Human Pathol 33: 21-28, 2002
13. Mezzelani A, Alasio L, Bonora MG, Pierotti MA, Rilke F, Pilotti S: c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 80: 519-525, 1999
14. O'Malley FP, Parkes R, Latta E, Tjan S, Zardo T, Mueller R, Arneson N, Blackstein M, Andrulis I: Comparison of HER-2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000
15. Pauletti G, Dandekar S, Rong HM, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. Am J Clin Pathol 115: 504-511, 2001
16. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE: HER-2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77: 148-154, 2002
17. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G: Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Nat Cancer Inst 93: 1141-1146, 2001
18. Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G: Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Cancer 92: 2965-2974, 2001
19. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positive do not get the message. J Clin Oncol 19: 2714-2721, 2001
20. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H: Amplification of HER-2/neu gene in HER-2/neu overexpressing and nonoverexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15: 116-124, 2002
21. Vergas-Roig LM, Gago FE, Tello O, Martin De Civetta MT, Ciocca DR: c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 84: 129-134, 1999
22. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P, Dogliotti L: Effects of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105-3110, 1996
23. Rasbridge SA, Gillet CE, Seymour AM, Patel K, Richards MA, Rubens RD, Millis RR: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335-341, 1994
24. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X: HER-2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94: 2169-2173, 2002
25. Fernandez JL, Goyanes V, Lopez-Fernandez IB, Gasalvez J: Quantification of C-ERB-B2 gene amplification in breast cancer cells using fluorescence in situ hybridization and digital image analysis. Cancer Genet Cytogenet 86: 18-21, 1996
26. Rogalla P, Helbig R, Drieschner N, Flohr AM, Krohn M, Bullerdiek J: Molecular-cytogenetic analysis of fragmentation of chromosome 17 in breast cancer cell line EFM-19. Anticancer Res 22: 1987-1992, 2002
27. Orsetti B, Courjal F, Cuny M, Rodriguez C, Theillet C: 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 18: 6262-6270, 1999
28. Latham C, Zhang A, Nalbanti A, Maner S, Zickert P, Blegen H, Zetterberg A: Frequent co-amplification of two different regions on 17q in aneuploid breast carcinomas. Cancer Genet Cytogenet 127: 16-23, 2001
29. Bieche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC, Lidereau R: Two distinct amplified regions at 17q11-21 involved in human primary breast cancer. Cancer Res 56: 3886-3890, 1996
30. Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI: Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62: 1481-1488, 2002
31. Kwong KY, Hung MC: A novel splice variant of HER-2 with increased transformation activity. Mol Carcinogenet 23: 62-68, 1998
32. Azios NG, Romero FJ, Denton MC, Doherty JK, Clinton GM: Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 20: 5199-5209, 2001